New Strategies for Increasing Diversity in Clinical Trials

In April 2022, FDA issued draft guidance on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic populations in the United States. In June 2022, the U.S. House of Representatives passed legislation intended to increase the diversity of the population’s enrolled in clinical trials of new drugs. As voluntary inclusivity becomes a thing of the past, pharmaceutical and biotechnology companies will need to move beyond platitudes around diversity in clinical trials and adopt novel methods for recruitment.

This session will present practical methods for identifying, reaching, recruiting, and retaining study participants using behavior science and strategic communication approaches that are culturally relevant, supported by influencers, integrated, and education and relationship-based.